Reading SGMT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGMT free→Reading SGMT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SGMT free→QuarterlyIQ Insights · SGMT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 12, 2026, Tim Walbert, a member of the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”), tendered his resignation from the Board, effective as of June 12, 2026. Mr. Walbert’s resignation from the Board was due to other commitments and not the result of any disagreement with the Company on any matter relating to t…
Compensatory arrangements and equity grants to existing officers.
(including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Entry into a Material Definitive Agreement. On April 27, 2026, Sagimet Biosciences Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the “ Underwriters ”) relating to an underwritten offering (the “ Offering ”) of 29,166,700 shares (the “ Shares ”) of the Company’s Series A common stock, par value $0.0001…
Results of Operations and Financial Condition. Sagimet Biosciences, Inc. (the “ Company ”) is furnishing with this Current Report on Form 8-K (the “Current Report”) certain unaudited preliminary financial information for the Company’s fiscal quarter ended March 31, 2026. Certain Unaudited Preliminary Financial Information The Company estimates that its cash, cash equivalents and marketable securities were approximately $104.5 million as of March 31, 2026. This amount is unaudited and prelimin…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Retirement of Chief Medical Officer On April 20, 2026, Eduardo Martins, M.D., D.Phil. provided notice to Sagimet Biosciences, Inc. (the “ Company ”) of his retirement from his role as Chief Medical Officer of the Company, effective as of April 20, 2026. Dr. Martins will continue to support the Company as an external scientific advisor.
Results of Operations and Financial Condition On March 11, 2026, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18…
Results of Operations and Financial Condition On November 13, 2025, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Sec…
Changes in Registrant’s Certifying Accountant. On August 18, 2025, the Audit Committee of the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) recommended and the Board approved (i) the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 and related interim periods and, concurrently, (ii) the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registere…
Results of Operations and Financial Condition On August 13, 2025, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 6, 2025, Sagimet Biosciences Inc. (the “Company”) entered into amended and restated executive employment agreements with certain of its executive officers pursuant to which certain severance provisions were modified to align with market practices, including a second amended and restated executive employment agreement with its principal exec…
Results of Operations and Financial Condition On May 8, 2025, Sagimet Biosciences Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 29, 2025 Merdad Parsey, M.D., Ph.D., current member of the board of directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”), notified the Board that he will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”), currently scheduled to be held on June 9, 2025. Dr. Parsey will conti…
(including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.